UPDATE: Piper Jaffray Initiates Coverage on Nektar Therapeutics on Expected Attractive Returns
November 27, 2013 at 10:53 AM EST
In a report published Wednesday, Piper Jaffray analyst Joshua E. Schimmer initiated coverage on Nektar Therapeutics (NASDAQ: NKTR ) with an Overweight rating and $20.00 price target. In the report, Piper Jaffray noted, “We are initiating, resuming or assuming coverage on 16 biotechnology companies. We believe the outlook for the